Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193,394,759
-
Total 13F shares
-
31,250,927
-
Share change
-
-5,624,184
-
Total reported value
-
$193,761,084
-
Put/Call ratio
-
54%
-
Price per share
-
$6.20
-
Number of holders
-
51
-
Value change
-
-$33,550,517
-
Number of buys
-
25
-
Number of sells
-
20
Institutional Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q3 2017
As of 30 Sep 2017,
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) was held by
51 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
31,250,927 shares.
The largest 10 holders included
QVT Financial LP, RTW INVESTMENTS, LP, PRIMECAP MANAGEMENT CO/CA/, D. E. Shaw & Co., Inc., BANK OF MONTREAL /CAN/, AXA, MORGAN STANLEY, K2 PRINCIPAL FUND, L.P., Point72 Asset Management, L.P., and BAKER BROS. ADVISORS LP.
This page lists
51
institutional shareholders reporting positions in this security
for the Q3 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.